These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1514478)

  • 41. Four against infection.
    Meyer C
    Am J Nurs; 1993 Apr; 93(4):68-72. PubMed ID: 8480806
    [No Abstract]   [Full Text] [Related]  

  • 42. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 43. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 44. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 45. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating drugs after their approval for clinical use.
    Ray WA; Griffin MR; Avorn J
    N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract]   [Full Text] [Related]  

  • 47. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
    Rogers AS; Israel E; Smith CR; Levine D; McBean AM; Valente C; Faich G
    Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 51. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 52. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 55. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
    [No Abstract]   [Full Text] [Related]  

  • 56. Postmarketing surveillance-one of the key issues in drug development.
    Székely G; Görgényi F
    Ther Hung; 1992; 40(4):147-53. PubMed ID: 1345020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adverse events and adverse reactions associated with drugs--important actual spontaneous reporting of the drug event].
    Homma M
    Ryumachi; 1992 Oct; 32(5):429-31. PubMed ID: 1440077
    [No Abstract]   [Full Text] [Related]  

  • 58. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
    BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
    [No Abstract]   [Full Text] [Related]  

  • 59. FDA will increase postmarketing surveillance of drugs.
    Tanne JH
    BMJ; 2004 Nov; 329(7476):1203. PubMed ID: 15550412
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug makers are still giving gifts to doctors, F.D.A. officials tell senators.
    Harris G
    N Y Times Web; 2005 Mar; ():A15. PubMed ID: 15948332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.